Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
GS$867.10-61.18(-6.59%)UPDATE 1-Goldman Sachs lowers gold price forecasts on hawkish Fed outlook5:22:31 PM ETMRNA$234.65-23.69(-9.17%)Health Canada Authorizes Moderna's mRNA Influenza and Combination Influenza and COVID-19 Vaccines5:20:44 PM ETAMPH$29.45+1.43(+5.10%)Amphastar Q3 revenue rises, beats expectations5:16:44 PM ETTMO$678.00+1.06(+0.16%)Thermo Fisher Scientific Authorizes $5 Billion of Share Repurchases5:15:01 PM ETPNC$223.20-10.25(-4.39%)PNC names Alexander Overstrom as CFO, succeeding Robert Reilly5:14:20 PM ETRKLB$45.65-6.58(-12.60%)Why Rocket Lab Stock Dropped Today5:11:01 PM ETCOST$1,065.590.00(0.00%)Jim Cramer Says Costco Is Still a Great Value. Charlie Munger's Rule Explains Why5:07:28 PM ETSVM$8.18-0.16(-1.92%)SILVERCORP REPORTS ADJUSTED NET INCOME OF $18.4 MILLION, $0.08 PER SHARE, AND CASH FLOW FROM OPERATING ACTIVITIES OF $62.7 MILLION FOR Q2 FISCAL 20275:06:04 PM ETNET$280.50+35.99(+14.72%)Cloudflare Q3 revenue beats estimates on AI platform demand5:05:25 PM ETINTC$51.94-6.34(-10.88%)Stock Market Today, Nov. 5: Intel Falls on Weak Fourth-Quarter Sales Outlook Amid Chip Selloff5:02:16 PM ETTMO$678.00+1.06(+0.16%)Thermo Fisher Scientific Announces Quarterly Dividend5:00:04 PM ETWPM$131.25-0.25(-0.19%)Wheaton Precious Metals Announces Third Quarter 2026 Results and Record Year-to-Date Production, Sales Volume, Revenue, Earnings and Cash Flow5:00:00 PM ETTSX:SAP$41.620.00(0.00%)Saputo Reports Financial Results for the Second Quarter of Fiscal 2027 Ended September 30, 20265:00:00 PM ETNET$280.50+35.99(+14.72%)Cloudflare Stock Surges on Lifted Full-Year Outlook, Third-Quarter Revenue Growth5:00:00 PM ETMNST$47.830.00(0.00%)Monster Beverage Q3 sales beat estimates as marketing investments boost results4:56:44 PM ETEOG$144.89-2.17(-1.48%)UPDATE 2-US shale producer EOG Resources beats profit estimates on higher crude prices4:55:18 PM ETCVX$213.17-3.79(-1.75%)Chevron (CVX) Price Forecast: Critical Support Faces First Major Test4:54:45 PM ETAAPL$342.50-7.06(-2.02%)Market Close: Stocks Tumble, Apple To Sell $7B In Debt, Wendy's Rejects Buyout Bid 11-5-20264:52:29 PM ETANTUPDATE 1-A&O Shearman's $1.1 billion AI plan builds on law firms' tech investments4:51:58 PM ETDNA$9.83-0.13(-1.31%)Ginkgo Bioworks Q3 revenue falls compared to last year4:51:51 PM ETABX$8.83-0.22(-2.43%)Abacus Global Management Q3 revenue, adjusted EBITDA beat estimates4:51:39 PM ETPRTA$7.89-0.50(-5.96%)Prothena Q3 net loss narrows on lower costs4:51:15 PM ETLRCX$193.80+8.60(+4.64%)BUZZ-Chip firm Lam Research rises after announcing $25 bln stock buyback4:50:28 PM ETEOG$144.89-2.17(-1.48%)EOG Resources Q3 revenue ease past estimates amid strong price realizations4:49:39 PM ET

PBYI · NASDAQ

Puma Biotechnology, Inc.

$9.54 -1.16 (-10.84%)

Company overview

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for patients with early-stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; and PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc., and sub-license agreements with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$492M
Employees
172
Headquarters
Los Angeles, CA
Website
pumabiotechnology.com
CEO
Alan H. Auerbach
Listed
April 24, 2012
P/E
19.23
Dividend yield
0.00%

Company financials

Revenue
$227M
Gross profit
$169M
Operating income
$29.5M
EBITDA
$43.8M
Net income
$24.4M
EPS
$0.50
Total assets
$193M
Total debt
$16M
Gross margin
74.46%
Net margin
10.73%
Earnings yield
5.20%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

6.407.739.0510.3711.70
PBYI 1D NASDAQ O10.47H10.85L10.32C10.70+0.48 (+4.70%)Vol367.32K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
PBYIPuma Biotechnology, Inc. Press release Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire
PBYIPuma Biotechnology, Inc. Press release Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2026 Financial Results Business Wire
PBYIPuma Biotechnology, Inc. Stock news 4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month Zacks Investment Research
PBYIPuma Biotechnology, Inc. Press release Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Business Wire
PBYIPuma Biotechnology, Inc. Stock news Comparing TG Therapeutics (NASDAQ:TGTX) and Puma Biotechnology (NASDAQ:PBYI) Defense World
PBYIPuma Biotechnology, Inc. Stock news PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins Zacks Investment Research
PBYIPuma Biotechnology, Inc. Press release Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer Business Wire
PBYIPuma Biotechnology, Inc. Press release Puma Biotechnology to Present at H.C. Wainwright’s 28th Annual Global Investment Conference Business Wire
PBYIPuma Biotechnology, Inc. Press release Puma Biotechnology to Present at H.C. Wainwright's 28th Annual Global Investment Conference Business Wire
PBYIPuma Biotechnology, Inc. Stock news Puma Biotechnology: NERLYNX Funds Their Potential Next Oncology Franchise Seeking Alpha
PBYIPuma Biotechnology, Inc. Press release Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire
PBYIPuma Biotechnology, Inc. Stock news Is Puma Biotechnology (PBYI) a Great Value Stock Right Now? Zacks Investment Research
PBYIPuma Biotechnology, Inc. Stock news PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised Zacks Investment Research
PBYIPuma Biotechnology, Inc. Stock news Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript Seeking Alpha
PBYIPuma Biotechnology, Inc. Stock news Puma Biotechnology Q2 Earnings Call Highlights MarketBeat
PBYIPuma Biotechnology, Inc. Stock news Puma Biotech (PBYI) Q2 Earnings and Revenues Top Estimates Zacks Investment Research
PBYIPuma Biotechnology, Inc. Press release Puma Biotechnology Reports Second Quarter 2026 Financial Results Business Wire
PBYIPuma Biotechnology, Inc. Press release Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results Business Wire
PBYIPuma Biotechnology, Inc. Stock news Puma Biotechnology Q1 Earnings Call Highlights MarketBeat
PBYIPuma Biotechnology, Inc. Stock news PBYI Q1 Earnings & Sales Beat Estimates, 2026 Guidance Raised Zacks Investment Research
See more
FAQ

Questions about Puma Biotechnology, Inc.

What does Puma Biotechnology, Inc. do?
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for patients with early-stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; and PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc., and sub-license agreements with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
What is PBYI's market cap?
Puma Biotechnology, Inc. (PBYI) is a listed stock with a live quote. The latest market cap on this page is $492M.
Where is Puma Biotechnology, Inc. headquartered?
Puma Biotechnology, Inc. is headquartered in Los Angeles, CA.
How do I get PBYI news from the API?
Call GET /v1/news?tickers=PBYI. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does PBYI news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for PBYI, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the PBYI price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs